ClinicalTrials.gg
CompletedNCT06129409Updated Oct 27, 2026

Effects of NT-0796 in Obese Participants at Risk of Cardiovascular Disease

A Phase 1 interventional study of NT-0796 in Cardiovascular Diseases, sponsored by Rezera (formerly NodThera Limited). Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Rezera (formerly NodThera Limited) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Apr 2024, 2 years 7 months ago, and no results have been posted to the registry.
Updated Oct 27, 2026Sponsor changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
67
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This trial is a Randomized, Double-Blind (Sponsor-Open), Placebo-Controlled Study to Assess the Effect of NT-0796 on Inflammation in Obese Participants at Risk of Cardiovascular Disease.

Participants will be admitted to an in-patient Clinical Research Unit on Day -1 and will be discharged on Day 30. The trial will include a 7-day out-patient safety follow-up period following the last dose of study treatment.

For the first approximately 20 participants effect of food will be evaluated on the Pharmacokinetics of NT-0796. MRI's will be conducted in a subset of participants.

Read the detailed description

The goal of this clinical trial is to evaluate the effects of NT-0796 on inflammation in obese participants at risk of cardiovascular disease, evaluate the effects of NT-0796 on body weight and composition, to see how safe NT-0796 is, and how well it is tolerated and to measure the blood levels of NT-0796, with and without food.

02

Conditions studied

  • Cardiovascular Diseases
03

In context

Cardiovascular Diseases

5,370 studies on the registry are indexed under Cardiovascular Diseases; 939 are open to participants now.

This study's enrollment of 67 is below the median of 100 across 3,084 interventional studies indexed under Cardiovascular Diseases.

Browse Cardiovascular Diseases studies →

Lead sponsor

Rezera (formerly NodThera Limited) is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female aged 18 years or older.
  2. (BMI) ≥30 and ≤40 kg/m2 at screening.
  3. Presence of 1 or more of the following risk factors for atherosclerotic cardiovascular disease:

    • History of controlled hypertension
    • History of hypercholesterolemia
    • History of high-density lipoprotein levels
    • Controlled Type 1 or Type 2 Diabetes mellitus

Exclusion criteria

Exclusion Criteria:

  1. History of stroke with residual neurological deficit within 2 years or within 6 months
  2. History of acute coronary syndrome (ACS)
  3. Stable angina.
  4. Diagnosis of congestive heart failure
  5. Evidence of past or current infection with or
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
67 participants (actual)

Study arms

  • Experimental
    NT-0796

    BID

    Drug: NT-0796

  • Placebo comparator
    Placebo

    BID

    Drug: NT-0796

Interventions

  • Orally administered capsules

06

What researchers measure

Primary outcomes

  1. Change in hsCRP levels

    Evaluate the effects of NT-0796 on inflammation.

    Time frame: Baseline to Day 28

Secondary outcomes

  1. Change in Body weight (kg)

    Time frame: Change from baseline to Day 28

  2. Body composition

    Absolute Fat mass, % Body Fat and Visceral Fat (L)

    Time frame: Change from baseline to Day 28

Other outcomes

  1. Clinical laboratory values

    Haematology and Clinical Chemistry

    Time frame: Change from baseline to Day 28

  2. Vital signs

    Body temperature, heart rate and systolic and diastolic blood pressure

    Time frame: Change from baseline to Day 28

07

Study locations

2 sites
  • Investigative Site
    Miami, Florida 33147, United States
  • Investigative Site
    Austin, Texas 78744, United States
08

References and documents

Publications

  • Ray KK, Clarke N, Thornton P, Miles AE, Digby Z, Davies MJ, Gorman M, Mullen B, Reader V, Magill M, Johnstone H, Ariti C, Sattar N, Marx N, Navar AM, Hernandez AF, George JT, Watt AP, Butler J, Ridker PM. Anti-Inflammatory Effects of Oral NLRP3 Inhibition With Ruvonoflast Among Individuals at Elevated Cardiovascular Risk. J Am Coll Cardiol. 2026 May 26:S0735-1097(26)06570-8. doi: 10.1016/j.jacc.2026.05.014. Online ahead of print. PubMed 42187339 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2023 to primary completion in Apr 2024, 6 months.

Of 53 industry-sponsored phase 1 interventional studies under Cardiovascular Diseases, half reached primary completion within 3 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 15. This study's 6 months is above that.

Counting every sponsor, half of 96 studies reached it within 15 months; a quarter within 3 and three quarters within 45.

Cardiovascular Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2023
First posted
Nov 13, 2023
StartActual
Oct 10, 2023
Primary completionActual
Apr 15, 2024
CompletionActual
Apr 15, 2024
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 42187339 ↗
Oct 27, 2026
Sponsor
NodThera Limited→Rezera (formerly NodThera Limited)
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 42187339 ↗
    Sponsor NodThera Limited→Rezera (formerly NodThera Limited)
    + 3 other changes: index terms, identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06129409
Lead sponsor
Rezera (formerly NodThera Limited)
Responsible party
Sponsor
First posted
Nov 13, 2023
Start date
Oct 10, 2023
Primary completion
Apr 15, 2024
Completion
Apr 15, 2024
Last update
Oct 27, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ruvonoflast

Start the discussion